Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.42 |
| ▸ | MME | P08473 | 5/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.37 |
| ▸ | QRFPR | Q96P65 | 2/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | NMT2 | O60551 | 2/20 | 0.34 |
| ▸ | NMT1 | P30419 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30674928 | 1.00 | TGFBR1 (0.42) | TGFBR1MMEPTGS1GSTK1QRFPR | |
| SCHEMBL29475227 | 1.00 | TGFBR1 (0.42) | TGFBR1MMEPTGS1GSTK1QRFPR | |
| SCHEMBL29714329 | 1.00 | TGFBR1 (0.42) | TGFBR1MMEPTGS1GSTK1QRFPR | |
| SCHEMBL29597633 | 1.00 | TGFBR1 (0.42) | TGFBR1MMEPTGS1GSTK1QRFPR | |
| SCHEMBL29530629 | 1.00 | TGFBR1 (0.42) | TGFBR1MMEPTGS1GSTK1QRFPR | |
| SCHEMBL30956646 | 0.97 | TGFBR1 (0.40) | TGFBR1MMEPTGS1GSTK1QRFPR | |
| SCHEMBL31424011 | 0.97 | TGFBR1 (0.40) | TGFBR1MMEPTGS1GSTK1QRFPR | |
| SCHEMBL31423993 | 0.97 | TGFBR1 (0.40) | TGFBR1MMEPTGS1GSTK1QRFPR | |
| SCHEMBL30988909 | 0.97 | TGFBR1 (0.40) | TGFBR1MMEPTGS1GSTK1QRFPR | |
| SCHEMBL30956647 | 0.97 | TGFBR1 (0.40) | TGFBR1MMEPTGS1GSTK1QRFPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4039710-B1 | ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123 | SANOFI SA (FR) | 2026-03-25 | — | — | EP | disclosed |
| EP-4453236-B1 | METHODS AND SYSTEMS FOR ANALYZING TARGET ENGAGEMENT DATA FROM BIOLOGICAL ASSAYS | US HEALTH (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250130234-A1 | METHODS AND SYSTEMS FOR ANALYZING TARGET ENGAGEMENT DATA FROM BIOLOGICAL ASSAYS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-04-24 | — | — | US | disclosed |
| US-12168681-B2 | Il-2 variants with reduced binding to IL-2 receptor alpha and uses thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| EP-4453236-A1 | METHODS AND SYSTEMS FOR ANALYZING TARGET ENGAGEMENT DATA FROM BIOLOGICAL ASSAYS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2024-10-30 | — | — | EP | disclosed |
| WO-2024194649-A1 | ENGINEERED T CELLS AND USES THEREOF | Quell Therapeutics Limited (GB) | 2024-09-26 | — | — | WO | disclosed |
| US-20240067690-A1 | IL-2 VARIANTS WITH REDUCED BINDING TO IL-2 RECEPTOR ALPHA AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230416725-A1 | SYSTEMS FOR GENE EDITING AND METHODS OF USE THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-12-28 | — | — | US | disclosed |
| US-11834485-B2 | IL-2 variants with reduced binding to IL-2 receptor alpha and uses thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230257756-A1 | REAL-TIME CELLULAR THERMAL SHIFT ASSAY (RT-CETSA) FOR RESEARCH AND DRUG DISCOVERY | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023122685-A1 | METHODS AND SYSTEMS FOR ANALYZING TARGET ENGAGEMENT DATA FROM BIOLOGICAL ASSAYS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-4192976-A1 | REAL-TIME CELLULAR THERMAL SHIFT ASSAY (RT-CETSA) FOR RESEARCH AND DRUG DISCOVERY | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-4139341-A1 | IL-2 VARIANTS WITH REDUCED BINDING TO IL-2 RECEPTOR ALPHA AND USES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4039710-A2 | ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123 | SANOFI (FR) | 2022-08-10 | — | — | EP | disclosed |
| CN-114230668-A | anti-CD 3 antibodies, anti-CD 123 antibodies, and bispecific antibodies that specifically bind to CD3 and/or CD123 | 赛诺菲 | 2022-03-25 | — | — | CN | disclosed |
| CN-114230667-A | anti-CD 3 antibodies, anti-CD 123 antibodies, and bispecific antibodies that specifically bind to CD3 and/or CD123 | 赛诺菲 | 2022-03-25 | — | — | CN | disclosed |
| WO-2022060707-A1 | SYSTEMS FOR GENE EDITING AND METHODS OF USE THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022035743-A1 | REAL-TIME CELLULAR THERMAL SHIFT ASSAY (RT-CETSA) FOR RESEARCH AND DRUG DISCOVERY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-02-17 | — | — | WO | disclosed |